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Abstract
Background: The aim of this study was to assess the validity of the 7
th edition of the American Joint Committee
on Cancer (AJCC) TNM system (TNM-7) for patients undergoing hepatectomy for hepatocellular carcinoma (HCC).
Methods: Partial hepatectomies performed for 879 patients from 1993 to 2005 were retrospectively reviewed.
Clinicopathological factors, surgical outcome, overall survival (OS), and disease-free survival (DFS) were analyzed to
evaluate the predictive value of the TNM-7 staging system.
Results: According to the TNM-7 system, differences in five-year survival between stages I, II, and III were
statistically significant. Subgroup analysis of stage III patients revealed that the difference between stages II and IIIA
was not significant (OS, p = 0.246; DFS, p = 0.105). Further stratification of stages IIIA, IIIB and IIIC also did not
reveal significant differences. Cox proportional hazard models of stage III analyses identified additional
clinicopathological factors affecting patient survival: lack of tumor encapsulation, aspartate aminotransferase (AST)
values > 68 U/L, and blood loss > 500 mL affected DFS whereas lack of tumor encapsulation, AST values > 68 U/L,
blood loss > 500 mL, and serum a-fetoprotein (AFP) values > 200 ng/mL were independent factors impairing OS.
Stage III factors including tumor thrombus, satellite lesions, and tumor rupture did not appear to influence survival
in the stage III subgroup.
Conclusions: In terms of 5-year survival rates, the TNM-7 system is capable of stratifying post-hepatectomy HCC
patients into stages I, II, and III but is unable to stratify stage III patients into stages IIIA, IIIB and IIIC. Lack of tumor
encapsulation, AST values > 68 U/L, blood loss > 500 mL, and AFP values > 200 ng/mL are independent
prognostic factors affecting long-term survival.
Keywords: American Joint Committee on Cancer, Tumor encapsulation, Hepatocellular carcinoma, Partial hepatect-
omy, TNM-7
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers observed world-wide [1,2]. This form of can-
cer is especially prevalent in Taiwan due to the high
number of carriers of chronic hepatitis B and is commonly
observed among subjects in the 6
th decade [3,4].
Several therapeutic approaches have been developed for
the treatment of HCC. Surgical resection is the treatment
of choice for resectable forms of the disease. In addition to
liver transplantation, resection is advocated as a potentially
curative treatment. With recent improvements in surgical
techniques and postoperative management, hospital mor-
talities have been reduced to values approaching zero,
with morbidities ranging from 10 to 25% [5-7]. However,
long term prognoses vary widely due to the lack of coher-
ent staging systems.
Several staging systems with different prognostic pre-
dictors and treatment algorithms have been proposed.
The most commonly used are the Barcelona Clinic Liver
Cancer [BCLC] [8], Cancer of the Liver Italian Program
[CLIP] [9], and Tumor-Node-Metastasis [TNM] [10] sys-
tems in Europe and in the United States, the Okuda [11]
and Japan Integrated Staging [JIS] [12] scores in Japan,
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staging system in China. However, unlike other types of
cancer, the prognosis of HCC is determined not only by
the anatomical involvement and growth pattern of the
tumor but also by pathophysiological features such as the
presence of liver cirrhosis and the grade of residual liver
function [14-17].
The American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) TNM sys-
tem is one of the most commonly used staging systems.
TNM staging for HCC is focused on the impact of extra-
hepatic spread, lymph node involvement, and tumor
characteristics such as size (5 cm), vascular invasion, and
satellite lesions. The new 7
th edition (TNM-7) of the
AJCC/UICC TNM system [10], which was introduced in
2009, is a modified version of the 6
th edition (TNM-6) of
this system. The major modifications of this new system
are: stage IIIA includes only multiple tumors or any
tumor larger than 5 centimeters (T3a); stage IIIB includes
only tumors of any size involving a major portal vein or
hepatic vein (T3b); and T4 status is shifted to stage IIIC
(Figure 1). These modifications bring new issues to
ongoing debates over tumor staging. The purpose of the
present study, therefore, was to assess the validity of the
TNM-7 staging system for a large series of patients with
resectable HCC at a single center.
Materials and methods
Patients
Between January 1993 and June 2005, 879 patients with
HCC underwent hepatic resections at the Linkou Chang
Gung Memorial Hospital. All enrolled patients were
staged according to the 7th edition of the AJCC/UICC
TNM system and analyzed retrospectively. Because this
study was aimed to evaluate the prognostic value of this
new TNM system for resectable HCC, patients classified
with stages IVA and IVB were excluded. Clinicopathologi-
cal factors for these patients were also analyzed. Patients
with incomplete clinical data or who were lost follow-up
were excluded.
6
th Edition  7
th edition   
T- staging   
T3   Multiple tumors >5cm or tumor 
involving a major branch of portal 
or hepatic vein(s) 
T3a  Multiple tumors >5cm 
T3b  Single tumor or multiple tumors of any 
size involving a major branch of the PV 
or HV 
Stage Grouping   
Stage I    T1  N0  M0  Stage I  T1  N0  M0 
Stage II    T2  N0  M0  Stage II  T2  N0  M0 
Stage IIIA  T3  N0  M0  Stage IIIA  T3a  N0  M0 
        Stage IIIB  T3b  N0  M0 
Stage IIIB  T4  N0  M0  Stage IIIC  T4   N0  M0 
Stage IIIC  Any T  N1  M0  Stage IVA  Any T  N1   M0 
Stage IV  Any T  Any N  M1  Stage IVB  Any T  Any N  M1 
Figure 1 The 6
th and 7
th editions of the American Joint Committee on Cancer (AJCC) TNM staging system.
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Before 1995, the preoperative evaluation relied on preo-
perative liver function and Child-Pugh status of the
patients. After 1995, the algorithm for selecting patients
for hepatectomy was according to Makuuchi’s criteria
and indocyanine green retention rate at 15 minutes (ICG
R15) [18,19].
Operative technique
During surgery, the abdomen was explored through a
subcostal incision with a midline xyphoid extension or
through a Mercedes star incision. Intraoperative ultraso-
nography was routinely performed in order to confirm
resectability and evaluate the relationship between the
resection line and major vascular structures. Inflow con-
trol with the Pringle maneuver was commonly applied
intermittently. Hemivascular control was performed in
selected right or left hepatectomies. Before 2002, all the
resections were performed with peon-crushing technique.
After that period, the liver parenchyma was divided with
clamp-crushing technique or ultrasonic dissector (CUSA)
according to the surgeon’s preference, without influen-
cing the postoperative outcome as previously reported
[20,21].
Follow up
After surgery, all patients were followed every 3 months in
the out-patient clinic with regular determinations of
serum a-fetoprotein (AFP) concentration and with
imaging studies, such as abdominal ultrasonography or
computed tomography (CT). When recurrence was sus-
pected, abdominal CT or hepatic angiography was per-
formed. Disease free survival (DFS) was defined as the
period from the date of hepatectomy to the date of recur-
rence as detected by imaging studies. Overall survival (OS)
was defined as the period from the date of hepatectomy to
the date of death.
Statistical analyses
Survival rates were calculated using the Kaplan-Meier
method, and survival curves were compared using the log-
rank test. Continuous dataw e r ee x p r e s s e da sm e d i a n s
with interquartile ranges. To identify the clinicopathologi-
cal factors with independent prognostic significance, mul-
tivariate analysis was performed using a Cox regression
model. In all analyses, a p value of less than 0.05 was con-
sidered statistically significant. All statistical analyses were
performed using SPSS version 13.0 software (SPSS Inc.,
Chicago, IL, USA).
Results
Long-term outcome of resectable HCC as stratified by
TNM-7 staging
The clinicopathological characteristics of 879 patients with
resectable HCC are summarized in Table 1. The operative
mortality rate was 4.0% (n = 35) and the surgical compli-
cation rate was 26.5%. Major hepatectomy, defined as the
resection of more than three segments, was performed in
Table 1 Clinicopathological characteristics of 879 patients with resectable hepatocellular carcinoma
Number of patients (%) or median (25-75 percentile)
Age (years) 58 (47-66)
Male/female 707 (80.4)/172 (19.6)
Hepatitis B virus positive, hepatitis C virus positive 549 (66.7), 285 (38.5)
CTP status: A/B or C 821 (93.4)/58 (6.6)
ICG retention rate at 15 min (%) 9.7 (5.7-16.4)
Albumin (g/dL) 4.1 (3.8-4.4)
Bleeding (> 500 mL) 401 (45.9)
Mortality 35 (4.0)
AFP (ng/mL) 66.8 (9.7-770.0)
Tumor size (cm) 4.0 (2.5-7.0)
Rupture 53 (6.0)
Cirrhosis 507 (57.7)
Macro/microvascular invasion 188 (21.4)/104 (11.8)
Satellite lesions 229 (26.1)
Encapsulation 627 (71.3)
Resection margin positive 37 (4.2)
Grade 432 (49.1)/447 (50.9)
Well and moderate differentiated/poorly and undifferentiated
CTP, Child-Pugh status; AFP, a-fetoprotein; Grade: Edmonson and Steiner; ICG, indocyanine green
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formed in 504 (57.3%) patients. Among these patients, 844
were enrolled for DFS and OS analyses. HCC was staged
according to the criteria of the 7
th edition of the AJCC/
UICC TNM staging system. All patients were followed
regularly at 3-month intervals for clinical evaluation,
laboratory data collection and imaging studies. The med-
ian follow-up period was 54.8 months. Of these 844
patients, 66.7% were positive for HBV infection, 38.5%
were positive for HCV infection, and 57.7% had liver cir-
rhosis. Of those with liver cirrhosis, 93.4% were Child-
Pugh class A.
The 1-, 3-, 5-, 8-, and 10-year DFS rates in this series
were 65.2%, 43.3%, 33.4%, 27.2%, and 25.8.0%, respec-
tively, whereas the 1-, 3-, 5-, 8-, and 10-year OS rates
were 85.3%, 67.2%, 54.7%, 40.0%, and 32.8%, respec-
tively. After 5 years, statistically significant differences in
survival were observed between patients with stages I, II,
and III disease according to the TNM-7 (p <0 . 0 5f o r
each group analysis; Figures 2a and 2b).
Patients with stage III underwent further subgroup ana-
lysis. The 5-year OS and DFS were analyzed by pairwise
comparison (Table 2, Figures 3a and 3b). Although some
trends toward sub-classification of stage III HCC were
apparent, differences between stages II and IIIA were not
statistically significant (OS, p = 0.246; DFS, p = 0.105).
Upon further stratification of stages IIIA, IIIB, and IIIC,
differences remained statistically insignificant (Figure 3).
Cox proportional hazard models of stage III analysis
Subgroup analyses of 257 patients with stage III, 44
patients with stage IIIA, 158 patients with stage IIIB, and
55 patients with stage IIIC HCC were performed using
the Cox proportional hazard model (Table 2). To identify
additional important prognostic factors for stage III
HCC, 12 clinicopathological factors including 6 patholo-
gical characteristics, 3 liver function tests, 2 surgical
factors, and AFP values were analyzed. Lack of tumor
encapsulation, AST values > 68 U/L, and blood loss >
500 mL were found to be independent significant prog-
nostic factors affecting DFS. Moreover, lack of encapsula-
tion, presence of vascular invasion, AST values > 68 U/L,
blood loss > 500 mL, and AFP values > 200 ng/mL were
found to be independent significant prognostic factors in
the OS analysis. Stage III patients included those with
tumor thrombus, satellite lesions, or rupture. Interest-
ingly, these factors did not appear to be significant in the
Cox proportional hazard model.
Discussion
The AJCC/UICC TNM system is a widely used staging
model for HCC patients. The most remarkable change
in the 7
th edition is the dichotomization of stage IIIA by
T3a and T3b (Figure 1). Findings of the present study,
which intended to assess the validity of this new staging
system for resectable HCC, revealed that this system
was clearly capable of stratifying patients with stages I,
II, and III in terms of 5-year survival rates. However,
the TNM-7 failed to stratify stage III patients into stages
IIIA, IIIB, and IIIC. The TNM-6 system was reported in
2006 to be superior to the TNM-5 system with respect
to clinical relevance and prognostic value, but a surgical
margin greater than 1 cm, ICG-R15 more than 10%,
AST values > 90 U/L, and male gender were also found
to be independent prognostic factors in multivariate
analysis [22]. In the current evaluation of the TNM-7
staging system, stratification was not successful for
b







Figure 2 Cumulative survival rates according to TNM-7 staging
system of stages I, II and III. a. Cumulative disease-free survival
rates according to TNM-7 staging system of stages I, II and III. b.
Cumulative overall survival rates according to TNM-7 staging system
of stages I, II and III.
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Cox proportional model disclosed that other factors,
such as the lack of tumor encapsulation, AST values
> 68 U/L, and blood loss > 500 mL, independently
affected survival. These findings support the hypothesis
that HCC patients usually present with other confound-
ing factors that affect the long-term outcomes. A staging
system should be capable of accounting for these factors
and the most important drawback of the TNM-7 staging
system is the lack of incorporation of host and surgical
factors.
Staging systems are designed to predict prognosis and to
define the most suitable treatment. Several staging classifi-
cations have been proposed, but currently no consensus
exists regarding the best stratification for clinical practice
[23-25]. Investigators utilizing the Akaike information cri-
terion to compare 5 cancer staging systems among 1713
patients with early to advanced stages of HCC concluded
that the CLIP staging system is the best long-term prog-
nostic model and that its predictive accuracy is indepen-
dent of treatment strategy [26]. In another investigation
comparing 7 different staging systems for a cohort of
HCC patients who underwent transarterial chemoemboli-
zation, the CLIP score was also found to provide the best
prognostic stratification on the basis of the Akaike infor-
mation criterion [27]. Almost all staging systems can stra-
tify effectively in the context of a large scale patient
population, but most staging systems have their own pre-
diction inaccuracies. In a separate study comparing the
B C L C ,A J C CT N M - 7 ,a n dC h i n e s es t a g i n gs y s t e m s ,t h e
Chinese and BCLC staging systems were found to be
superior to the TNM-7 staging system in stratification and
prognosis prediction. However, the subgroups of stage III
patients were not well-stratified according to the TNM-7
classification [24]. The present study, which addresses the
pros and cons of the TNM-7 system for resectable HCC,
reveals that the accuracy of stratification is lost for the
stage III population subgroup. Moreover, AFP values >
200 ng/mL, tumor encapsulation, and hepatitis (AST
values > 68 U/L) were found to represent additional
important factors affecting treatment outcome.
Liver function variables (ascites, bilirubin, alkaline
phosphatase, and albumin concentrations) and host
health status (male gender, performance state, and age)
have also been reported to serve as major prognostic fac-
tors [28]. A unique characteristic of HCC is that the
combination of viral infection, cirrhosis, and poor liver
functional reserve also affects the outcome. Poor liver
function reserve is an essential criterion for patient selec-
tion before resection. Consequently, patients with differ-
ent liver function states but with the same TNM stage
have different outcomes based on the probabilities of
treatment. In the present study, cirrhosis was not an
independent prognostic factor for stage III patients,
although cirrhosis was associated with delayed recurrence
of small HCC (data not shown). These findings are com-
patible with those of others [29].
Classification of stages I-II in the TNM-7 staging sys-
tem did not change as compared to the TNM-6 staging
system. In both systems, solitary lesions without vascular
invasion and satellite lesions are classified as stage I and
outcome is independent of tumor size. However, the
association between tumor size and tumor aggressiveness
is widely recognized [30].L a r g e rt u m o r s( >5c m )a r e
reported to be associated with greater likelihood of vas-
cular invasion and higher histologic grading [31,32]. The
biological behavior of tumors of different sizes and the
outcome of patients with tumors of different sizes may
not be uniform, and certainly the prognostic significance
of tumor size requires further reevaluation.
Table 2 Cox proportional hazard analysis of risk factors for 5-year overall and disease-free survival
Overall survival Disease-free survival
HR 95% C.I. p-value HR 95% C.I. p-value
Vascular invasion 1.39 1.14-1.70 < 0.01 1.15 0.94-1.40 0.18
Satellite lesions 1.23 1.03-1.47 0.03 1.17 0.97-1.40 0.10
Rupture 1.53 0.98-2.40 0.06 1.21 0.76-1.91 043
Cirrhosis 0.90 0.66-1.21 0.47 0.96 0.70-1.30 0.80
Encapsulation 0.67 0.49-0.91 0.01 0.73 0.53-0.99 0.04
Grade (III, IV vs. I, II) 1.02 0.98-1.14 0.71 1.05 0.94-1.17 0.42
Albumin 0.97 0.64-1.47 0.88 0.75 0.49-1.14 0.17
AST (> 68 vs. ≤ 68 U/L) 1.84 1.30-2.61 < 0.01 1.65 1.14-2.40 0.01
Bil (> 1.3 ≤ vs. ( 1.3 mg/dL) 1.40 0.89-2.02 0.16 0.98 0.64-1.14 0.91
AFP (200 ng/mL) 1.44 1.05-1.98 0.02 1.28 0.94-1.75 0.123
Blood loss (> 0.5 L) 1.85 1.36-2.53 < 0.01 1.43 1.05-1.94 0.03
Margin involved 0.84 0.63-1.12 0.29 0.78 0.59-1.04 0.09
Grade: Edmonson and Steiner; AST, aspartate aminotransferase; Bil, total bilirubin; AFP, a-fetoprotein ICG, indocyanine green
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chosen as end points and the outcomes were compatible
with those of other studies. Outcome differences between
stages I-II and between stages II-III were statistically sig-
nificant according to both the TNM-6 and the TNM-7
staging systems. However, the present study failed to dis-
criminate outcome differences for stages IIIA, IIB, and
IIIC. In this regard, it is of interest that staging systems
currently under development are incorporating new bio-
markers, such as lens culinaris agglutinin reactive AFP
[33,34], des-c-carboxy prothrombin [35], glypican 3 [36],
and osteopontin [37]. In the future, with regard to the goal
of a more personalized medicine, the customization of
scoring systems would ideally incorporate tumor patholo-
gical characteristics, host factors and, possibly, gene
expression profiles. Improvements in the prognostic pre-
dictability of staging systems would redefine treatment
strategies and such strategies may ultimately encompass
gene and target therapies.
Conclusions
In terms of 5-year survival rates, the 7
th edition of
AJCC/UICC TNM system (TNM-7) effectively stratifies
post-hepatectomy HCC patients into stages I, II, and III
but is incapable of stratifying stage III patients into
stages IIIA, IIIB, and IIIC. Lack of tumor encapsulation,
AST values > 68 U/L, blood loss > 500 mL, and AFP
values > 200 ng/mL are independent factors influencing
the long-term survival of these patients.
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Pairwise Comparisons   
 
Stage  
I   II   IIIA   IIIB   IIIC  
P-value 
Log Rank  I  
II   0.065 
IIIA   0.025  0.303 
IIIB   <0.001  <0.001  0.283 
IIIC    <0.001   <0.001  0.089  0.373 
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IIIC  
  <0.001 
 
<0.001 
0.106  0.944 
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according to TNM-7 staging system with subgroup analysis of stage III patients.
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